Cargando…
Advances in Age-related Macular Degeneration Understanding and Therapy
While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy for neovascular age-related macular degeneration (AMD) was a great success, the pathologic processes underlying dry AMD that eventually leads to photoreceptor dysfunction, death, and vision loss remain elusive...
Autores principales: | Miller, Joan W, Bagheri, Saghar, Vavvas, Demetrios G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683729/ https://www.ncbi.nlm.nih.gov/pubmed/29142592 http://dx.doi.org/10.17925/USOR.2017.10.02.119 |
Ejemplares similares
-
Neuroprotection for Age-Related Macular Degeneration
por: Lin, Jonathan B., et al.
Publicado: (2022) -
Age-Related Macular Degeneration (AMD): A View to the Future
por: Miller, Joan W., et al.
Publicado: (2021) -
Systemic Complement Activation Profiles in Nonexudative Age-Related Macular Degeneration: A Meta-Analysis
por: Lin, Jonathan B., et al.
Publicado: (2022) -
Systemic Complement Activation Profiles in Nonexudative Age-Related Macular Degeneration: A Systematic Review
por: Lin, Jonathan B., et al.
Publicado: (2022) -
Systemic Dyslipidemia in Age-related Macular Degeneration: An Updated Systematic Review and Meta-analysis
por: Li, Brandon, et al.
Publicado: (2023)